As the global pharmaceutical market evolves, the EU is losing ground in cutting-edge areas such as biologics and orphan medicines, not to mention new therapies. The reasons for this loss of competitiveness are similar to those that Draghi identifies in other sectors: fragmented and insufficient public investment in R&D, little support for private investment and an overly complex regulatory framework
Israel attacks the north of the Gaza Strip again, pro-Palestinian demonstrations intensify, Guterres calls for an end to the “bloodshed”
Translated News
- October 7, 2024
One day after one year since the start of the conflict in the Middle East, pro-Palestinian demonstrations are intensifying and there was a man who tried to set himself on…
